title: BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation.
abstract: Although approximately 10-20% cases of follicular lymphoma lack BCL2 gene rearrangement, there are few reports having described the alternative genetic aberrations and their association about clinicopathological features. In this study, analysis by Fluorescence in situ hybridization of BCL6 gene aberrations in 100 follicular lymphoma cases without IGH/BCL2 rearrangement resulted in the identification of four subgroups. Group I: BCL6 gene rearrangement (n=41); Group II: BCL6 gene amplification/3q27 gain (n=30); Group III: the absence of both (n=23); and Group IV: the presence of both (n=6). Group II showed higher grade morphology (Grade 3a/b: 93%), higher bcl2 and MUM1 expression (73 and 57%, respectively), and more frequent combination with BCL2 gene amplification/18q21 gain (90%) than the other groups. BCL6 gene aberration, especially amplification/3q27 gain, indicates the presence of certain morphological and phenotypical findings in follicular lymphoma cases without IGH/BCL2 rearrangement.
authors.affiliation: Department of Pathology, School of Medicine, Kurume University, Kurume, Japan. karube1975@yahoo.co.jp
authors.forename: Kennosuke
authors.initials: K
authors.lastname: Karube
authors.forename: Guo
authors.initials: G
authors.lastname: Ying
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tagawa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Niino
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Aoki
authors.forename: Yoshizo
authors.initials: Y
authors.lastname: Kimura
authors.forename: Keiko
authors.initials: K
authors.lastname: Hashikawa
authors.forename: Nobuko
authors.initials: N
authors.lastname: Suefuji
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Sugita
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nomura
authors.forename: Kay
authors.initials: K
authors.lastname: Shimizu
authors.forename: Shirou
authors.initials: S
authors.lastname: Yoshida
authors.forename: Masao
authors.initials: M
authors.lastname: Seto
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002871:Chromosome Banding; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D015321:Gene Rearrangement; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D050835:Interferon Regulatory Factors / Q000235:genetics / Q000378:metabolism; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D051560:Proto-Oncogene Proteins c-bcl-6; D014178:Translocation, Genetic; D000099218:Interferon Regulatory Factor-4
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D050835:Interferon Regulatory Factors; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D000099218:Interferon Regulatory Factor-4; C084103:BCL6 protein, human